Durga referenced that a small percentage of those patients were previously treated, but essentially mostly treatment-naive patients, and how they compared to when they were compared to two milligram aflibercept as the control.

You know, Jay, you really set out the landscape nicely here.

We've had, you know, excellent clinical trial results from both the YOSEMITE and RINE and the Photon studies.

In YOSEMITE and RINE, twenty-two percent of patients were treatment-experienced with a washout period.

So washout meaning for three months leading up to the trial, they could not have been treated with anything, okay? The rest, the majority, were treatment naive.

This is an enormous study.

This is the largest DME study to date at that time.

How can I decide which patients I can extend really quickly, to Durga's point, one or two injections, and then, hey, come back in three months, versus the patient who I really need to watch beyond just looking at fluid? Is there another way for me to sort of predict that? But I'm curious if you have any other unmet needs you think that would really impact your practice and other people's practices.